Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Dr Sara M. Tolaney on Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer
August 08, 2018
Dr Dennis P. Scanlon on Recent Attempts to Address Clinician Burnout
August 06, 2018
Dr Dennis P. Scanlon Explains Costs Associated With the Opioid Epidemic
July 27, 2018
Dr Michael Thompson Outlines Challenges With the Mass Adoption of EHRs, Precision Medicine
July 25, 2018
Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer
July 23, 2018
Currently Reading
Dr Peter Paul Yu Explains Current Challenges With Precision Medicine
July 18, 2018
Dr Peter Paul Yu on Progress in the Move Toward Interoperability
July 06, 2018
Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting
July 05, 2018
Leonard Saltz: Novel Approaches to Colon Cancer, Behaviors That Impact Survival
July 02, 2018
Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer
June 28, 2018
Dr Victoria Villaflor Discusses How Novel Therapies Have Changed Cancer Treatment
June 26, 2018
Dr Peter Paul Yu: How Next-Generation Sequencing is Changing Cancer Care
June 21, 2018
Dr James Lin Chen on the Shift to Precision Medicine
June 18, 2018
Ellen Miller Sonet: The Importance of Cancer Care Providers Informing Patients of Treatment Costs
June 17, 2018
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16, 2018
Dr Leonard B. Saltz: The Role of Next-Generation Sequencing in Advancing Precision Medicine
June 14, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018

Dr Peter Paul Yu Explains Current Challenges With Precision Medicine

We need to bring together our real-world data and our reimbursement systems to recognize the fact that a lot of what could be gained by precision medicine is going to be based on a lot of research, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.


We need to bring together our real-world data and our reimbursement systems to recognize the fact that a lot of what could be gained by precision medicine is going to be based on a lot of research, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.

Transcript

What current challenges are there in precision medicine?

I think that the number of drugs that are either FDA approved or compendium listed based on precision medicine test is still fairly small; maybe a couple dozen or less. There are many more drugs in the pipeline, of course, but a lot of those will crash and burn on the way and never make it. So, there is a lot of work to be done in drug development to identify drugs that are effective and tolerable for a target, and we’re still very much in the research world realm of development.

We need to bring together our real-world data and our reimbursement systems to recognize the fact that a lot of what could be released and gained by precision medicine is going to be based on a lot of research, and unless we find a way to fund it at a time when we’re still in the research mode, you’d be very slow to realize the benefits of precision medicine.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!